We confirmed the modulation of selected genes in the Imprime + DC-101 combination treatment group as shown by increased expression of M1 genes Nos2 and Tnfa and downmodulation of M2 genes Mrc1, Il10, and Tgfb. The M1 phenotype and functionality of tumor infiltrating macrophages were further confirmed by flow cytometric detection of high CD86 expression and increased TNF-α production post-LPS stimulation (Figures 8C). This evidence concerns the gene MRC1 and neoplasm.